Article Text
PDF
Abstract
Objective To assess the role of flash glucose monitoring in early and late changes in glycemic markers under real-life conditions.
Research design and methods Deidentified glucose results from 6802 flash glucose monitors were analyzed after dividing into high, medium and low-risk groups based on tertiles of time spent in hypoglycemia (min/day <70 mg/dL) or hyperglycemia (hours/day >240 mg/dL). Groups were further subdivided into tertiles of glucose scanning frequency and glycemic measures analyzed in the first 14 days and over 6 months.
Results Improvement in dysglycemia mainly occurred in the first month of device use. Comparing first and last 14 study days, high-hyperglycemic-risk individuals showed reduced time >240 mg/dL (mean±SEM) from 6.07±0.06 to 5.73±0.09 hours/day (p<0.0001). High-frequency scanners showed 0.82 hours/day reduction in hyperglycemia (p<0.0001) whereas low-frequency scanners failed to demonstrate a benefit. High-hypoglycemic-risk individuals showed reduction in time ≤54 mg/dL from 90±1 to 69±2 min/day (p<0.0001) comparing first and last 14 study days. This reduction was evident in both low and high-frequency scanners but with reduced hyperglycemic exposure in the latter group.
Conclusions Under real-world conditions, flash monitoring is associated with rapid and sustained reduction in dysglycemia with high-frequency scanners demonstrating more significant reduction in hyperglycemia.
- flash glucose monitoring
- continuous glucose monitoring
- longitudinal
- diabetes
- glycemia
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0
Statistics from Altmetric.com
Footnotes
Presented at Portions of these data were presented at the 11th International Conference on Advanced Technologies and Treatments for Diabetes, Vienna, Austria, 14–17 February 2018.
Contributors SJ, TD, YX, GH, and RAA designed the study. SJ and YX performed the data analysis. SJ, TD, YX, GH, and RAA all critically reviewed the manuscript and provided intellectual content and feedback. All authors reviewed the manuscript before submission. SJ is the guarantor of the study and takes responsibility for the content of the article.
Funding This work was funded by Abbott Diabetes Care.
Competing interests SJ, TD, YX, and GH are employees of Abbott Diabetes Care. RAA received honoraria and research support from Abbott Diabetes Care but none in relation to the development of this work.
Patient consent Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Supporting data sets analyzed for the current study are available from the corresponding author on reasonable request.